Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Role of Combination Therapy in Women With Refractory Overactive Bladder
NCT06438861 · University of Alabama at Birmingham · NA · withdrawn · last registry update 2026-02-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Not funded by industry” | – | Registry record, University of Alabama at Birmingham |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-06Results posted on the registry: NYU Langone Health, a drug against ADRB3 (NCT04403165)
- 2026-11-05Phase 3 first posted: Suez Canal University, Articaine Hydrochloride With Epinephrine + Diclofenac Sodium (NCT07919938)
- 2026-11-04Phase 3 first posted: Ain Shams University, Trimetazidine + Standard Treatment (NCT07916922)
- 2026-10-30Results posted on the registry: Paul Hoff, Adjunct Exparel (bupivacaine liposome suspension 1.3%) (NCT03420638)
- 2026-10-29Results posted on the registry: University of Maryland, Baltimore, Duloxetine (NCT04111627)
- 2026-10-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Donor-derived Mesenchymal Stromal Cells + alemtuzumab (NCT03504241)
- 2026-10-28Also stopped (terminated): Algemeen Ziekenhuis Maria Middelares, Plasma-lyte (static group) + Norepinephrine (static group) (NCT06080178)
- 2026-10-28Also stopped (withdrawn): Aarhus University Hospital, Weak steroid (Flurolon, Allergan) + Potent steroid (Maxidex, Alcon) (NCT01682421)
- 2026-10-28Results posted on the registry: Heron Therapeutics, Bupivacaine HCl (NCT03705065)
- 2026-10-28Results posted on the registry: Heron Therapeutics, MMA regimen + HTX-011 (NCT06109428)
- 2026-10-27Results posted on the registry: Heron Therapeutics, HTX-011 + Bupivacaine Hydrochloride (NCT06109415)
- 2026-10-23Also stopped (terminated): Vanderbilt University Medical Center, Droxidopa + Midodrine (NCT02897063)
- 2026-10-22Also stopped (terminated): Cynata Therapeutics Limited, CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) + Placebo (NCT05643638)
- 2026-10-19Results posted on the registry: Allay Therapeutics, Inc., ATX101 + bupivacaine hydrochloride (NCT06799845)
- 2026-10-16Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, autologous circulating extracellular vesicles + Glucocorticoids (NCT07878559)
- 2026-10-16Results posted on the registry: Eli Lilly and Company, Placebo + Lebrikizumab (NCT06280716)
- 2026-10-16Also stopped (terminated): Insel Gruppe AG, University Hospital Bern, Gadobutrol (Gadovist/Gadavist) + Gadopiclenol (NCT07040865)
- 2026-10-15Results posted on the registry: Brigham and Women's Hospital, [F-18]PBR06 + [C-11]Methylreboxetine (NCT04144257)
- 2026-10-14Also stopped (terminated): Yale University, Phenylephrine + Norepinephrine (NCT04218773)
- 2026-10-06Results posted on the registry: Janssen Research & Development, LLC, Aticaprant (NCT05518149)
- 2026-10-06Also stopped (terminated): Janssen Research & Development, LLC, Aticaprant (NCT05518149)
- 2026-10-05Results posted on the registry: Ankara City Hospital Bilkent, Sevoflurane (Volatile Anesthetic) + Propofol 1% (NCT07092046)
- 2026-10-02Also stopped (suspended): Columbia University, Steroid Injection (NCT03722303)
- 2026-09-28Phase 3 first posted: Charite University, Berlin, Germany, Dehydroepiandrosterone (DHEA) + Placebo (NCT07843927)
- 2026-09-14Also stopped (withdrawn): Neurocrine UK Limited, Chronocort® + Standard Care (NCT03532022)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision